Mechanical ventilation (MV) for status asthmaticus (SA) is associated with high mortality \[[@B1]\]. Prolonged isoflurane (ISO) administration has been shown to be a safe and well-tolerated therapy in ICU patients and is a predictedable bronchodilator \[[@B2],[@B3]\]. We report our 10 years\' experience with MV and use of isoflurance (ISO) as a therapy for refractory SA.

Results
=======

Twenty-six of 47 patients (age 40 ± 20 years; 40 females) admitted to our ICU required MV. Cause for asthma exacerbation was infection in 57% of patients. Admission respiratory and heart rate, mean blood pressure, PO~2~, PCO~2~and pH was 37 ± 14, 127 ± 22 bpm 100 ± 23 mmHg, 133 ± 101 torr, 48 ± 29 torr, and 7.30 ± 0.18, respectively. Six of 26 patients received ISO (dose, 84 ± 106 MAC hours) for 87 ± 109 hours (range 8--227 hours). Hypotension occurred in all ISO patients and in one non-ISO patient, who was adequately treated with fluid (100%), and one inotrope in 3/6 ISO patients. Continuous paralysis was required in five patients. Patients who received ISO required a longer duration of MV and ICU length of stay (LOS) (Table [1](#T1){ref-type="table"}). There were no pneuomothoraces, air embolism or significant hypoxia in any patient. Five patients received sodium bicarbonate infusions for acidosis. Three patients in the ISO group died: one anoxic encephalopathy (VSA arrest prior to admission), one withdrawal of life support due to comorbid diseases, and one cardiac arrest (cause unknown). Two patients died in the non-ISO group; one anoxic encephalopathy (VSA arrest prior to admission) and one withdrawal of life support (comorbid diseases). None died due to failure to oxygenate/ventilate.

                           Non-ISO   ISO
  ------------------------ --------- -----------
  Total hours ventilated   74 ± 86   158 ± 180
  ICU LOS                  4 ± 4     8 ± 8
  Continuous paralysis     3         2
  Mortality                3         2

Conclusions
===========

Inhalational isoflurane anesthesia is a useful bronchodilator therapy in patients with severe exacerbations of asthma and should be considered in patients who do not respond adequately to conventional bronchodilator therapy.
